The Rein Therapeutics, Inc. (RNTX) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and registration statements that describe its clinical programs, financing arrangements, and regulatory milestones. These documents provide primary-source detail on how the clinical-stage biopharmaceutical company is advancing therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications.
Among the most relevant filings for RNTX are multiple Form 8-K reports. These include descriptions of the Phase 2 RENEW trial of LTI-03 in IPF, FDA communications regarding a clinical hold and its subsequent resolution, and regulatory authorizations from European agencies for trial sites in the United Kingdom, Germany, and Poland. Other 8-Ks outline the structure and terms of a Pre-Paid Advance Agreement and a Standby Equity Purchase Agreement with an affiliate of Yorkville Advisors, as well as later disclosure that Rein elected to terminate these agreements after taking specified advances and without incurring penalties.
Investors can also review the company’s S-1 registration statement, which summarizes Rein’s business overview, risk factors, and details of the Yorkville standby equity facility, including the number of shares registered for potential resale. Together, these filings explain how Rein describes its lead candidate LTI-03, its second candidate LTI-01 for loculated pleural effusions, and the associated orphan drug and Fast Track designations.
On Stock Titan, AI-powered tools can help interpret lengthy RNTX filings by highlighting key sections on clinical trial design, regulatory status, and financing terms. Users can quickly locate information on material agreements, capital structure changes, and important clinical or regulatory events disclosed in Rein Therapeutics’ SEC documents.
Rein Therapeutics, Inc. Schedule 13G/A reports detailed beneficial‑ownership disclosures by a Bios/Cavu investor group, listing shared voting and dispositive power across multiple Bios funds and related entities. The filing shows aggregate named positions (examples: 7,797,502 shares / 9.99% for several affiliated holders) and explains a 9.99% beneficial‑ownership blocker tied to the Series X Preferred Stock. The cover pages are used to populate Item 4 ownership figures and the filing includes a notice regarding dissolution of the group; further filings will be made by members in their individual capacities if required.
Rein Therapeutics, Inc. ownership disclosure: a Lynwood group reports beneficial ownership of 4,750,000 shares of Common Stock, representing 6.1% of the class as of May 4, 2026. The percentages are based on 78,039,032 shares outstanding as of May 4, 2026.
The Schedule 13G names Lynwood Capital Management Inc., Benjamin Shapiro and Lynwood Opportunities Master Fund as reporting persons and states the Fund directly beneficially owns the reported shares, with the Investment Manager and Mr. Shapiro potentially deemed to beneficially own those shares.
Rein Therapeutics, Inc. ownership disclosure: Funicular Funds, LP (with related Cable Car Capital, LP and Jacob Ma‑Weaver) reports beneficial ownership of 5,195,000 shares of Common Stock, equal to 6.7% of the class. The filing states the position includes 420,000 warrants that are subject to a blocker provision preventing exercise that would increase beneficial ownership above 4.99%. The filing ties its percent calculation to 78,039,032 shares outstanding as reported in a Rule 424(b)(5) Prospectus filed May 4, 2026.
Rein Therapeutics, Inc. disclosure: Laurence W. Lytton reports beneficial ownership of 4,500,000 shares of Common Stock, representing 5.8% of the class. The filing cites 78,039,032 shares outstanding following the issuer's issuance and sale of 50,000,000 shares as reported in a Rule 424(b)(5) prospectus.
Rein Therapeutics, Inc. entered into an underwriting agreement with Konik Capital Partners for an underwritten public offering of 50,000,000 shares of common stock at $1.00 per share. This represents gross proceeds of $50 million and expected net proceeds of about $46.1 million.
The underwriter has a 45-day option to buy up to 7,500,000 additional shares. Rein issued underwriter warrants equal to 3% of the shares sold, exercisable at $1.50 per share until April 30, 2031. The company also agreed with Bios Partners to defer conversion of 12,232 preferred shares, impose a lock-up on related securities until April 30, 2029, and issue Bios warrants for 3,000,000 common shares at $1.00 per share. Rein expects the proceeds, together with existing cash, to fund operations into 2028 and fully fund its Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.
Rein Therapeutics, Inc. proposes to sell 50,000,000 shares of common stock at a public offering price of $1.00 per share, with a 45-day underwriter option to purchase up to an additional 7,500,000 shares. Net proceeds are estimated at approximately $46.1 million (or $53.1 million if the option is exercised in full) and are expected to be used for working capital and general corporate purposes, including repayment of $5.375 million in unsecured promissory notes issued earlier in 2026. The offering includes issuance of underwriter warrants equal to 3% of the shares sold exercisable at $1.50 for five years, and the company has agreed to issue warrants to certain existing holders to purchase 3,000,000 shares at $1.00 at closing. The prospectus notes RENEW Phase 2 activity for lead candidate LTI-03, including first patient dosed in March 2026 and an expected interim topline readout in Q4 2026.
Rein Therapeutics, Inc. is registering 30,000,000 shares of common stock in a primary offering at an assumed price of $1.66 per share, with underwriters holding a 45‑day option for 4,500,000 additional shares. The Nasdaq‑listed company focuses on novel therapies for orphan pulmonary and fibrosis diseases, led by LTI‑03 for idiopathic pulmonary fibrosis, now in the global Phase 2 RENEW trial, with first patient dosed in March 2026 and interim topline data planned for the fourth quarter of 2026.
Rein recently received European orphan drug designation for LTI‑03 and has paused other programs to concentrate resources on this asset. As of December 31, 2025, it reported a net tangible book deficit of approximately $2.91 million and cash of $3.2 million, and raised $5.375 million via unsecured promissory notes in early 2026 that will be repaid from this offering. After the offering and repayment, adjusted net tangible book value is estimated at $0.65 per share, implying about $1.01 per‑share dilution at the assumed price. Management expects existing cash plus offering proceeds to fund operations through at least April 2027, primarily supporting LTI‑03 development and general corporate needs.
Rein Therapeutics, Inc. filed an amendment to its Annual Report for the year ended December 31, 2025 to replace Part III with full disclosures on directors, executive compensation, ownership, related-party transactions, and auditor fees that were previously expected to come from a proxy statement.
The company reports a classified five-member board with separate Chair and CEO roles, and the board considers all directors except CEO Brian Windsor to be independent under Nasdaq and SEC rules. Committees for audit, compensation, and nominating and governance are fully independent and met during 2025.
For 2025, CEO Brian Windsor received total compensation of $882,695, including a $575,000 salary and a $287,500 cash bonus, and holds significant option awards. Interim CFO Timothy Cunningham was paid through a consulting arrangement, receiving $433,940 in 2025. As of March 31, 2026, Windsor beneficially owned 1,057,691 shares (3.6%), while all directors and executive officers as a group held 4.4%. Major holders include Voss Capital at 15.9% and Bios-affiliated entities at 7.1%, before considering additional preferred and warrant overhangs subject to ownership caps.
The filing also outlines an April 2025 private transaction in which Bios-affiliated investors exchanged and bought pre-funded warrants at $1.599 per underlying share, and details a clawback policy, insider trading and anti-hedging restrictions, and 2025 audit fees of $548,225.
Rein Therapeutics, Inc. files its annual report outlining a focused but financially constrained rare-disease lung pipeline. The company is now centered on LTI‑03, an inhaled peptide for idiopathic pulmonary fibrosis, which has Orphan Drug Designation in the U.S. and EU and is in a global Phase 2 RENEW trial with the first patient dosed in March 2026.
Management discloses that existing cash, plus January and February 2026 financing proceeds, are expected to fund operations only into the second quarter of 2026, creating substantial doubt about continuing as a going concern without new capital. Because of these constraints, development of LTI‑01 for loculated pleural effusion and all preclinical programs has been paused indefinitely while resources are prioritized for LTI‑03. The report also highlights a history of net losses and material weaknesses in internal controls that the company is working to remediate, alongside a sizable in‑licensed patent estate around Cav1‑related peptides.